Skip to main content
Premium Trial:

Request an Annual Quote

Still Likely to Work

Uğur Şahin, the chief executive of BioNTech, says the vaccine his company developed with Pfizer should be effective against the new SARS-CoV-2 strain identified in the UK, the Guardian reports.

The strain, dubbed B.1.1.7, has led to concerns that it might be more easily transmitted than other SARS-CoV-2 stains, but as Science has reported, researchers are still trying to work out the significance of the new strain. 

According to the Guardian, Şahin says that as the proteins on this new strain are still highly similar to those on other strains, the vaccine still will likely be effective. "We don't know at the moment if our vaccine is also able to provide protection against this new variant," he adds. "But scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants."

Moncef Slaoui, the head scientific advisor to Operation Warp Speed in the US, similarly tells the New York Times that the new strain was unlikely to affect vaccine efficacy.

Şahin adds that if the vaccine does need to be tweaked to provide protection against this strain, that could be done in a few weeks, the Guardian says.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.